Odimma Therapeutics announced the presentation of new preclinical data supporting ODI-2001 at the ESMO Congress 2024 in Barcelona, Spain.
The data demonstrate antitumoral activity across multiple syngeneic tumor models, including the aggressive 4T1 breast cancer model, further supporting the potential of Odimma’s personalized combinatorial immunotherapy platform.
Presentation Details
Presentation Number: 1041P
Onsite Poster Display Date: Saturday, September 14, 2024
